Cellular Dynamics International Signs Agreement with Nanion Technologies to Enhance Mutual Offerings for Researchers

20-Sep-2017 Intellasia | BusinessWire | 9:01 PM Print This Post

MADISON, Wis.–(BUSINESS WIRE)–#IPSCCellular
Dynamics International (CDI), a FUJIFILM company
, the leading
developer and manufacturer of differentiated cells derived from human
induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH
(Nanion), a leading provider of instrumentation for ion channel drug
discovery and screening, announced today that they have entered into a
joint marketing agreement. The mutual partnership will offer research
customers access to CDI’s suite of human iPSC-derived tissue cells
paired with the high performance instrument platforms from Nanion to
drive functional readouts on human cell models.

Currently developed as a one year program, participating research
customers will receive Nanion’s CardioExcyte 96 instrument in
conjunction with a supply and participation agreement with CDI. Under
the program, CDI will provide iPSC-derived differentiated cells, Nanion
will provide on-site training for CardioExcyte 96 use. At the end of the
year, the customer’s contract can be renewed or the CardioExcyte 96
instrument can be purchased at a depreciated market value. Both
companies expect to continue to develop and expand their suite of
co-developed applications offered under this program.

“Cutting edge techniques can often be out of reach for many
investigators. This program increases testing equipment availability
while enabling researchers to take full advantage of the benefits
provided by CDI’s human iPSC-derived tissue specific cells,” said Dr.
Bruce Novich, Division President-CNBD for FUJIFILM Holdings America
Corporation and Division President – Life Sciences for CDI. “The net
result across the research community will be greater access to better
tools with more rapid generation of impactful results.”

“The CardioExcyte 96 measures electrical activity as well as cell
movement and changes in morphology. This is well suited for basic
research, toxicity testing, and therapeutic development across a suite
of endpoints including, but not limited to cardiac function, cell
attachment, spreading and proliferation, quantification of cell behavior
in a confluent layer, with regard to barrier function, and quality of
cell-cell and cell-substrate adhesions,” stated Niels Fertig, Founder
and CEO for Nanion Technologies GmbH. “CDI produces many cell types
central to these endpoints and we are excited to launch this combined
effort that bundles and increases access to these technologies.”

For more information please visit CDI at https://cellulardynamics.com/
and Nanion at http://www.nanion.de/.

About Cellular Dynamics International:

Cellular Dynamics International (CDI), a FUJIFILM company, is a leading
developer and supplier of human cells used in drug discovery, toxicity
testing, and regenerative medicine applications. Leveraging technology
that can be used to create induced pluripotent stem cells (iPSCs) and
differentiated tissue-specific cells from any individual, CDI is
committed to advancing life science research and transforming the
therapeutic development process in order to fundamentally improve human
health. The company’s inventoried iCell® products and donor-specific
MyCell® Products are available in the quantity, quality, purity, and
reproducibility required for drug and cell therapy development. For more
information please visit www.cellulardynamics.com.

About Fujifilm

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation
and leading-edge products to a broad spectrum of industries, including:
healthcare, with medical systems, pharmaceuticals and cosmetics; graphic
systems; highly functional materials, such as flat panel display
materials; optical devices, such as broadcast and cinema lenses; digital
imaging; and document products. These are based on a vast portfolio of
chemical, mechanical, optical, electronic, software and production
technologies. In the year ended March 31, 2017, the company had global
revenues of $21.5 billion, at an exchange rate of 108 yen to the dollar.
Fujifilm is committed to environmental stewardship and good corporate
citizenship. For more information, please visit: www.fujifilmholdings.com.

About Nanion

Nanion Technologies is a leading provider of instrumentation for ion
channel drug discovery and screening. Founded in 2002, Nanion has grown
over the last 15 years to a company with over 100 employees worldwide.
With headquarters in Munich, Germany, Nanion has subsidiaries in the
USA, Denmark, Japan and China, as well as distribution partners in seven
other countries. The Nanion team has developed and successfully
established four generations of automated patch clamp instruments for
sophisticated and high throughput applications in ion channel research
and drug discovery. www.nanion.de

All product and company names herein may be trademarks of their
registered owners.

Contacts

Fujifilm Contact:
Fujifilm
Lauren Geloso,
+1-914-798-8303
lgeloso@fujifilm.com
or
Nanion
Contact:

Nanion Technologies GmbH
Dr. Niels Fertig, +49 89
219095 072
info@nanion.de

 


Category: BusinessWire, PRAsia

Print This Post